Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)0.00 (0.00%)
Data as of 11/22/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $28.13 with a 52 week high of $33.43 and a 52 week low of $13.90.
Recent NewsMore >>
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
Audentes Therapeutics to Present at Upcoming Investor Conferences
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Upcoming EventsMore >>
Tuesday, November 28, 2017 11:00 a.m. ET
Piper Jaffray Healthcare Conference

Wednesday, November 29, 2017 11:45 a.m. ET
Evercore ISI Biopharma Catalyst/Deep Dive Conference

Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.